Lineage Cell Therapeutics tumbles after pricing $66M securities offering

seekingalpha
2024-11-20

Lineage Cell Therapeutics (NYSE:LCTX) shares tumbled 20% after pricing an offering to raise up to $66M.

The biotech entered into definitive agreements with certain investors and Broadwood Partners, an affiliate of its board member Neal Bradsher, for the purchase and sale of up to 39.47M common shares and accompanying warrants to purchase 39.47M shares at a combined price of $0.76 a share and accompanying warrant.

Each warrant will be exercisable at a price of $0.91 per common share. The potential gross proceeds to Lineage from the warrants, if fully exercised on a cash basis, will be ~$36M.

Lineage (LCTX) expects to receive $24M in aggregate gross proceeds from the offering with respect to the investments by the unaffiliated institutional investors, and around $6M from the offering with respect to the investment by Broadwood.

It currently plans to use the net proceeds from the offering for working capital and general corporate purposes, including research and development expenses and capital expenditures.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10